Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review.

Area of Science:

• Phytochemistry
• Pharmacology
• Toxicology

Background:

• Ashwagandha (Withania somnifera) is a widely used adaptogenic herb.
• Preclinical safety data for Ashwagandha is extensive, but clinical reports of adverse events exist.

Purpose of the Study:

• To review preclinical evidence on the safety of Ashwagandha (AS) and its constituents.
• To correlate preclinical findings with reported clinical cases, particularly liver toxicity.

Main Methods:

• Systematic review of preclinical studies (animal models, in vitro, cell culture).
• Analysis of reported clinical cases of Ashwagandha-induced toxicity.
• Evaluation of genotoxicity, mutagenicity, and other toxicological endpoints.

Main Results:

• Most studies indicate Ashwagandha is remarkably safe, with no genotoxicity or mutagenicity.
• Rare cases of reversible liver toxicity (cholestasis, jaundice) have been reported, not predicted by preclinical data.
• Constituents like withaferin-A show antitumorigenic effects; folkloric claims of abortion/sterility and cardiotoxicity lack preclinical support.

Conclusions:

• Ashwagandha is generally safe, but potential hepatotoxicity warrants further investigation into responsible constituents and patient factors.
• Preclinical data does not support folkloric claims of reproductive or cardiac toxicity.
• Withaferin-A demonstrates potential therapeutic applications in preclinical models.